HEXB

From WikiMD's Wellness Encyclopedia

HEXB[edit | edit source]

HEXB is a gene that encodes the beta subunit of the enzyme beta-hexosaminidase, which is crucial in the degradation of glycosphingolipids in the lysosome. Mutations in the HEXB gene can lead to a group of disorders known as GM2 gangliosidoses, including Sandhoff disease.

Structure[edit | edit source]

The HEXB gene is located on chromosome 5 (5q13.3) and spans approximately 40 kilobases. It consists of 14 exons and encodes the beta subunit of the beta-hexosaminidase enzyme. The enzyme itself is a dimer, composed of alpha and beta subunits, which are encoded by the HEXA and HEXB genes, respectively.

Function[edit | edit source]

The primary function of the HEXB gene product is to form part of the beta-hexosaminidase enzyme complex. This enzyme is responsible for the hydrolysis of terminal N-acetyl-D-hexosamine residues in glycoproteins, glycolipids, and glycosaminoglycans. In particular, it plays a critical role in the breakdown of GM2 gangliosides, which are complex molecules found in the neuronal cell membranes.

Clinical Significance[edit | edit source]

Mutations in the HEXB gene can lead to a deficiency in beta-hexosaminidase activity, resulting in the accumulation of GM2 gangliosides in the central nervous system. This accumulation is toxic to neurons and leads to the clinical manifestations of GM2 gangliosidoses.

Sandhoff Disease[edit | edit source]

Sandhoff disease is an autosomal recessive lysosomal storage disorder caused by mutations in the HEXB gene. It is characterized by progressive neurodegeneration, developmental delay, and early death. Symptoms typically appear in infancy and include muscle weakness, loss of motor skills, and seizures.

Diagnosis[edit | edit source]

Diagnosis of HEXB-related disorders is typically made through a combination of clinical evaluation, biochemical assays to measure beta-hexosaminidase activity, and genetic testing to identify mutations in the HEXB gene.

Treatment[edit | edit source]

Currently, there is no cure for disorders caused by HEXB mutations. Treatment is primarily supportive and may include physical therapy, medications to manage symptoms, and nutritional support. Research into gene therapy and enzyme replacement therapy is ongoing.

Research[edit | edit source]

Ongoing research into HEXB and related disorders focuses on understanding the molecular mechanisms of the disease, developing animal models, and exploring potential therapeutic approaches such as gene therapy and small molecule drugs.

See Also[edit | edit source]

References[edit | edit source]

Contributors: Prab R. Tumpati, MD